Dendreon Says Provenge On Track For Steady Growth, Downplays Rising Competition
This article was originally published in The Pink Sheet Daily
In an earnings call Nov. 2, Dendreon reported Q3 growth in sales and uptake of its prostate cancer active immunotherapy Provenge despite near term pressures.
You may also be interested in...
Plus news on recent financings by TopiVert, Dendreon, Inhibitex and Celsion.
In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.
Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.